INDV
Indivior Pharmaceuticals, Inc.
Price Chart
Latest Quote
$40.40
-1.07 (-2.58%)
Current Price
| Previous Close | $41.47 |
| Open | $41.50 |
| Day High | $42.07 |
| Day Low | $40.40 |
| Volume | 477,206 |
Stock Information
| Shares Outstanding | 118.20M |
| Total Debt | $509.00M |
| Cash Equivalents | $175.00M |
| Revenue | $1.29B |
| Net Income | $252.00M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.78B |
| P/E Ratio | 20.72 |
| EPS (TTM) | $1.95 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.39B |
| Sales | $1.29B |
| Income | $252.00M |
| Book/sh | $-1.18 |
| Cash/sh | $1.48 |
| Employees | 827 |
Financial Ratios
| Quick Ratio | 0.59 |
| Current Ratio | 0.86 |
| EPS Growth TTM | 89.40% |
Returns & Margins
| ROA | 22.65% |
| Gross Margin | 84.96% |
| Operating Margin | 46.06% |
| Profit Margin | 19.53% |
Ownership
| Insider Ownership | 4.30% |
| Institutional Ownership | 107.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.18 |
| P/S | 3.70 |
| P/B | -34.24 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $50.71 |
Technical Indicators
| SMA20 | $37.74 |
| SMA50 | $36.85 |
| SMA200 | $32.34 |
| RSI | 71.13 |
| ATR | 1.2129 |
| Shares Float | 110.14M |
| Short Float | 12.72% |
| Short Ratio | 5.31 |
| Volatility | 1.17 |
| Rel Volume | 0.28 |
Performance History
| Week | +6.51% |
| Month | +6.85% |
| Quarter | +33.51% |
| 6 Months | +10.84% |
| YTD | +13.07% |
| Year | +190.23% |
| 3 Years | +76.50% |
| 5 Years | +257.52% |
| 10 Years | +143.37% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $40.40 | 477,206 |
| 2026-06-24 | $41.47 | 2,243,300 |
| 2026-06-23 | $39.96 | 1,562,700 |
| 2026-06-22 | $38.32 | 1,234,700 |
| 2026-06-18 | $38.30 | 4,276,900 |
| 2026-06-17 | $37.93 | 1,485,100 |
| 2026-06-16 | $38.01 | 1,255,900 |
| 2026-06-15 | $38.40 | 1,145,300 |
| 2026-06-12 | $38.48 | 627,500 |
| 2026-06-11 | $38.13 | 1,840,300 |
| 2026-06-10 | $38.09 | 2,103,600 |
| 2026-06-09 | $38.26 | 1,639,200 |
| 2026-06-08 | $37.39 | 1,152,800 |
| 2026-06-05 | $37.62 | 1,586,800 |
| 2026-06-04 | $37.45 | 1,910,800 |
| 2026-06-03 | $35.43 | 1,535,300 |
| 2026-06-02 | $33.71 | 2,917,400 |
| 2026-06-01 | $34.88 | 2,069,200 |
| 2026-05-29 | $36.02 | 1,670,000 |
| 2026-05-28 | $36.61 | 1,242,100 |
| 2026-05-27 | $37.11 | 2,282,400 |
| 2026-05-26 | $37.81 | 1,648,000 |
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
đ° Latest News
IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects
Investor's Business Daily âĸ 2026-06-25T15:24:48Z
Reasons Why Investors Should Consider Betting on Indivior Stock
Zacks âĸ 2026-06-25T13:27:00Z
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Zacks âĸ 2026-06-25T12:40:00Z
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Zacks âĸ 2026-06-24T14:13:00Z
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Zacks âĸ 2026-06-24T14:05:00Z
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Zacks âĸ 2026-06-23T14:59:00Z
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Zacks âĸ 2026-06-23T14:52:00Z
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Zacks âĸ 2026-06-19T14:35:00Z
Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
Zacks âĸ 2026-06-19T12:14:00Z
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
Zacks âĸ 2026-06-19T12:04:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $246,000,000 | $231,000,000 | $174,000,000 | $151,000,000 |
| Cost Of Revenue | $246,000,000 | $231,000,000 | $174,000,000 | $151,000,000 |
| Total Revenue | $1,239,000,000 | $1,188,000,000 | $1,093,000,000 | $901,000,000 |
| Operating Revenue | $1,239,000,000 | $1,188,000,000 | $1,093,000,000 | $901,000,000 |
| Expenses | ||||
| Interest Expense | $45,000,000 | $41,000,000 | $35,000,000 | $27,000,000 |
| Total Expenses | $974,000,000 | $954,000,000 | $846,000,000 | $686,000,000 |
| Other Income Expense | $-3,000,000 | - | $-401,000,000 | $-296,000,000 |
| Net Non Operating Interest Income Expense | $-23,000,000 | $-18,000,000 | $8,000,000 | $-8,000,000 |
| Interest Expense Non Operating | $45,000,000 | $41,000,000 | $35,000,000 | $27,000,000 |
| Operating Expense | $728,000,000 | $723,000,000 | $672,000,000 | $535,000,000 |
| Other Operating Expenses | $-3,000,000 | $4,000,000 | $-9,000,000 | $-8,000,000 |
| Selling And Marketing Expense | $315,000,000 | $255,000,000 | $236,000,000 | $218,000,000 |
| General And Administrative Expense | $319,000,000 | $357,000,000 | $329,000,000 | $251,000,000 |
| Total Other Finance Cost | - | - | $1,000,000 | $-1,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $210,000,000 | $7,000,000 | $-126,000,000 | $-44,000,000 |
| Net Interest Income | $-23,000,000 | $-18,000,000 | $8,000,000 | $-8,000,000 |
| Interest Income | $22,000,000 | $23,000,000 | $43,000,000 | $19,000,000 |
| Normalized Income | $212,634,000 | $161,840,000 | $222,455,172 | $189,840,000 |
| Net Income From Continuing And Discontinued Operation | $210,000,000 | $7,000,000 | $-126,000,000 | $-44,000,000 |
| Total Operating Income As Reported | $262,000,000 | $38,000,000 | $-152,000,000 | $-81,000,000 |
| Net Income Common Stockholders | $210,000,000 | $7,000,000 | $-126,000,000 | $-44,000,000 |
| Net Income | $210,000,000 | $7,000,000 | $-126,000,000 | $-44,000,000 |
| Net Income Including Noncontrolling Interests | $210,000,000 | $7,000,000 | $-126,000,000 | $-45,000,000 |
| Net Income Continuous Operations | $210,000,000 | $7,000,000 | $-126,000,000 | $-45,000,000 |
| Pretax Income | $239,000,000 | $20,000,000 | $-145,000,000 | $-89,000,000 |
| Special Income Charges | $-3,000,000 | $-196,000,000 | $-401,000,000 | $-296,000,000 |
| Interest Income Non Operating | $22,000,000 | $23,000,000 | $43,000,000 | $19,000,000 |
| Operating Income | $265,000,000 | $234,000,000 | $247,000,000 | $215,000,000 |
| Gross Profit | $993,000,000 | $957,000,000 | $919,000,000 | $750,000,000 |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $1.64 | $-0.36 | $0.01 | $-0.38 |
| Basic EPS | $1.68 | $-0.36 | $0.01 | $-0.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $-366,000 | $-41,160,000 | $-52,544,828 | $-62,160,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $307,000,000 | $285,000,000 | $306,000,000 | $250,000,000 |
| Total Unusual Items | $-3,000,000 | $-196,000,000 | $-401,000,000 | $-296,000,000 |
| Total Unusual Items Excluding Goodwill | $-3,000,000 | $-196,000,000 | $-401,000,000 | $-296,000,000 |
| Reconciled Depreciation | $20,000,000 | $28,000,000 | $15,000,000 | $16,000,000 |
| EBITDA (Bullshit earnings) | $304,000,000 | $89,000,000 | $-95,000,000 | $-46,000,000 |
| EBIT | $284,000,000 | $61,000,000 | $-110,000,000 | $-62,000,000 |
| Diluted Average Shares | $128,048,780 | $132,309,000 | $141,800,000 | $145,617,000 |
| Basic Average Shares | $125,000,000 | $132,309,000 | $137,306,000 | $139,012,000 |
| Diluted NI Availto Com Stockholders | $210,000,000 | $7,000,000 | $-126,000,000 | $-44,000,000 |
| Tax Provision | $29,000,000 | $13,000,000 | $-19,000,000 | $-44,000,000 |
| Other Special Charges | $3,000,000 | $196,000,000 | $401,000,000 | $296,000,000 |
| Research And Development | $97,000,000 | $107,000,000 | $116,000,000 | $74,000,000 |
| Selling General And Administration | $634,000,000 | $612,000,000 | $565,000,000 | $469,000,000 |
| Other Gand A | $319,000,000 | $357,000,000 | $329,000,000 | $251,000,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $0 | $0 |
| Restructuring And Mergern Acquisition | - | $1,000,000 | $162,000,000 | $0 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-101,000,000 | $-344,000,000 | $-205,000,000 | $-19,000,000 |
| Total Assets | $1,201,000,000 | $1,316,000,000 | $1,760,000,000 | $1,769,000,000 |
| Total Non Current Assets | $550,000,000 | $489,000,000 | $494,000,000 | $510,000,000 |
| Other Non Current Assets | $27,000,000 | $39,000,000 | $28,000,000 | $18,000,000 |
| Non Current Deferred Assets | $323,000,000 | $277,000,000 | $288,000,000 | - |
| Non Current Deferred Taxes Assets | $323,000,000 | $277,000,000 | $288,000,000 | $219,000,000 |
| Goodwill And Other Intangible Assets | $2,000,000 | $7,000,000 | $13,000,000 | $70,000,000 |
| Current Assets | $652,000,000 | $827,000,000 | $1,266,000,000 | $1,259,000,000 |
| Other Current Assets | $13,000,000 | $11,000,000 | $52,000,000 | $13,000,000 |
| Prepaid Assets | $34,000,000 | $31,000,000 | $23,000,000 | $14,000,000 |
| Inventory | $155,000,000 | $178,000,000 | $135,000,000 | $114,000,000 |
| Receivables | $255,000,000 | $287,000,000 | - | - |
| Taxes Receivable | $2,000,000 | $33,000,000 | $0 | $5,000,000 |
| Accounts Receivable | $253,000,000 | $254,000,000 | $254,000,000 | $220,000,000 |
| Allowance For Doubtful Accounts Receivable | $-4,000,000 | $-3,000,000 | $-2,000,000 | $-2,000,000 |
| Gross Accounts Receivable | $257,000,000 | $257,000,000 | $256,000,000 | $222,000,000 |
| Cash Cash Equivalents And Short Term Investments | $195,000,000 | $320,000,000 | $410,000,000 | $893,000,000 |
| Cash And Cash Equivalents | $195,000,000 | $319,000,000 | $316,000,000 | $774,000,000 |
| Investmentin Financial Assets | - | $27,000,000 | $41,000,000 | $98,000,000 |
| Other Intangible Assets | - | $5,000,000 | $8,000,000 | $70,000,000 |
| Restricted Cash | - | $0 | $415,000,000 | - |
| Non Current Prepaid Assets | - | - | $19,000,000 | $20,000,000 |
| Debt | ||||
| Net Debt | $124,000,000 | $14,000,000 | - | - |
| Total Debt | $351,000,000 | $375,000,000 | $283,000,000 | $277,000,000 |
| Long Term Debt And Capital Lease Obligation | $312,000,000 | $347,000,000 | $271,000,000 | $266,000,000 |
| Long Term Debt | $290,000,000 | $315,000,000 | $237,000,000 | $237,000,000 |
| Current Debt And Capital Lease Obligation | $39,000,000 | $28,000,000 | $12,000,000 | $11,000,000 |
| Current Debt | $29,000,000 | $18,000,000 | $3,000,000 | $3,000,000 |
| Other Current Borrowings | $29,000,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,300,000,000 | $1,653,000,000 | $1,952,000,000 | $1,718,000,000 |
| Total Non Current Liabilities Net Minority Interest | $386,000,000 | $729,000,000 | $662,000,000 | $699,000,000 |
| Other Non Current Liabilities | $22,000,000 | $17,000,000 | $32,000,000 | $428,000,000 |
| Current Liabilities | $914,000,000 | $924,000,000 | $1,290,000,000 | $1,019,000,000 |
| Other Current Liabilities | $-1,000,000 | $12,000,000 | $39,000,000 | $79,000,000 |
| Payables And Accrued Expenses | $773,000,000 | $824,000,000 | $1,167,000,000 | - |
| Payables | $70,000,000 | $93,000,000 | $74,000,000 | $61,000,000 |
| Total Tax Payable | $22,000,000 | $30,000,000 | $35,000,000 | $24,000,000 |
| Income Tax Payable | $2,000,000 | - | - | - |
| Accounts Payable | $48,000,000 | $63,000,000 | $39,000,000 | $33,000,000 |
| Other Payable | - | - | $28,000,000 | $4,000,000 |
| Equity | ||||
| Common Stock Equity | $-99,000,000 | $-337,000,000 | $-192,000,000 | $51,000,000 |
| Total Equity Gross Minority Interest | $-99,000,000 | $-337,000,000 | $-192,000,000 | $51,000,000 |
| Stockholders Equity | $-99,000,000 | $-337,000,000 | $-192,000,000 | $51,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-30,000,000 | - | $-53,000,000 | - |
| Other Equity Adjustments | $-30,000,000 | - | $-53,000,000 | - |
| Retained Earnings | $-243,000,000 | $-443,000,000 | $-295,000,000 | $1,303,000,000 |
| Other | ||||
| Ordinary Shares Number | $125,024,430 | $124,903,000 | $136,526,357 | $136,480,995 |
| Share Issued | $125,024,430 | $124,903,000 | $136,526,357 | $136,480,995 |
| Tangible Book Value | $-101,000,000 | $-344,000,000 | $-205,000,000 | $-19,000,000 |
| Invested Capital | $220,000,000 | $-4,000,000 | $48,000,000 | $291,000,000 |
| Working Capital | $-262,000,000 | $-97,000,000 | $-24,000,000 | $240,000,000 |
| Capital Lease Obligations | $32,000,000 | $42,000,000 | $43,000,000 | $37,000,000 |
| Total Capitalization | $191,000,000 | $-22,000,000 | $45,000,000 | $288,000,000 |
| Additional Paid In Capital | $112,000,000 | $90,000,000 | $88,000,000 | $14,000,000 |
| Capital Stock | $62,000,000 | $62,000,000 | $68,000,000 | $68,000,000 |
| Common Stock | $62,000,000 | $62,000,000 | $68,000,000 | $68,000,000 |
| Non Current Accrued Expenses | $52,000,000 | $365,000,000 | $359,000,000 | - |
| Long Term Capital Lease Obligation | $22,000,000 | $32,000,000 | $34,000,000 | $29,000,000 |
| Current Capital Lease Obligation | $10,000,000 | $10,000,000 | $9,000,000 | $8,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $103,000,000 | $60,000,000 | $72,000,000 | - |
| Current Accrued Expenses | $703,000,000 | $731,000,000 | $1,093,000,000 | $565,000,000 |
| Investments And Advances | $28,000,000 | - | - | - |
| Goodwill | $2,000,000 | $2,000,000 | $5,000,000 | $0 |
| Net PPE | $170,000,000 | $139,000,000 | $124,000,000 | $85,000,000 |
| Accumulated Depreciation | $-107,000,000 | $-90,000,000 | $-81,000,000 | $-77,000,000 |
| Gross PPE | $277,000,000 | $229,000,000 | $205,000,000 | $162,000,000 |
| Construction In Progress | $64,000,000 | $38,000,000 | $23,000,000 | - |
| Other Properties | $26,000,000 | $39,000,000 | $40,000,000 | - |
| Machinery Furniture Equipment | $76,000,000 | $76,000,000 | $77,000,000 | $102,000,000 |
| Land And Improvements | $111,000,000 | $76,000,000 | $65,000,000 | $51,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $75,000,000 | $94,000,000 | $63,000,000 | $45,000,000 |
| Work In Process | $49,000,000 | $51,000,000 | $34,000,000 | $42,000,000 |
| Raw Materials | $31,000,000 | $33,000,000 | $38,000,000 | $27,000,000 |
| Other Short Term Investments | $0 | $1,000,000 | $94,000,000 | $119,000,000 |
| Treasury Shares Number | - | $0 | $0 | $0 |
| Held To Maturity Securities | - | $27,000,000 | $41,000,000 | $98,000,000 |
| Long Term Provisions | - | - | $12,000,000 | $5,000,000 |
| Current Provisions | - | - | $407,000,000 | $303,000,000 |
| Buildings And Improvements | - | - | $11,000,000 | $9,000,000 |
| Available For Sale Securities | - | - | - | $98,000,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-94,000,000 | $5,000,000 | $-353,000,000 | $-9,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-27,000,000 | $36,000,000 | $-300,000,000 | $-4,000,000 |
| Cash Flow From Continuing Operating Activities | $-27,000,000 | - | $-299,000,000 | $-3,000,000 |
| Operating Gains Losses | $1,000,000 | - | $-10,000,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-67,000,000 | $-31,000,000 | $-53,000,000 | $-5,000,000 |
| Investing Cash Flow | $-66,000,000 | $69,000,000 | $-95,000,000 | $-222,000,000 |
| Cash Flow From Continuing Investing Activities | $-67,000,000 | - | $-95,000,000 | $-222,000,000 |
| Net Other Investing Changes | $1,000,000 | $-1,000,000 | $3,000,000 | $1,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-11,000,000 | $-173,000,000 | $-33,000,000 | $-90,000,000 |
| Issuance Of Capital Stock | $2,000,000 | $3,000,000 | $3,000,000 | $2,000,000 |
| Financing Cash Flow | $-30,000,000 | $-102,000,000 | $-64,000,000 | $-101,000,000 |
| Cash Flow From Continuing Financing Activities | $-31,000,000 | - | $-64,000,000 | $-101,000,000 |
| Net Other Financing Charges | $1,000,000 | $-2,000,000 | $-22,000,000 | $-10,000,000 |
| Net Common Stock Issuance | $-9,000,000 | $-170,000,000 | $-30,000,000 | $-88,000,000 |
| Common Stock Issuance | $2,000,000 | $3,000,000 | $3,000,000 | $2,000,000 |
| Other | ||||
| Repayment Of Debt | $-17,000,000 | $-240,000,000 | $-12,000,000 | $-3,000,000 |
| Issuance Of Debt | $0 | $332,000,000 | $0 | $0 |
| End Cash Position | $195,000,000 | $319,000,000 | $316,000,000 | $774,000,000 |
| Beginning Cash Position | $319,000,000 | $316,000,000 | $774,000,000 | $1,102,000,000 |
| Effect Of Exchange Rate Changes | $-1,000,000 | $0 | $1,000,000 | $-1,000,000 |
| Changes In Cash | $-123,000,000 | $3,000,000 | $-459,000,000 | $-327,000,000 |
| Proceeds From Stock Option Exercised | $-5,000,000 | $-22,000,000 | $-22,000,000 | $-10,000,000 |
| Common Stock Payments | $-11,000,000 | $-173,000,000 | $-33,000,000 | $-90,000,000 |
| Net Issuance Payments Of Debt | $-17,000,000 | $92,000,000 | $-12,000,000 | $-3,000,000 |
| Net Long Term Debt Issuance | $-17,000,000 | $92,000,000 | $-12,000,000 | $-3,000,000 |
| Long Term Debt Payments | $-17,000,000 | $-240,000,000 | $-12,000,000 | $-3,000,000 |
| Long Term Debt Issuance | $0 | $332,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $0 | $100,000,000 | $84,000,000 | $-218,000,000 |
| Sale Of Investment | $20,000,000 | $117,000,000 | $129,000,000 | $27,000,000 |
| Purchase Of Investment | $-20,000,000 | $-17,000,000 | $-45,000,000 | $-245,000,000 |
| Net Business Purchase And Sale | $0 | $0 | $-129,000,000 | $0 |
| Purchase Of Business | $0 | $0 | $-129,000,000 | $0 |
| Net Intangibles Purchase And Sale | $-1,000,000 | $-2,000,000 | $-45,000,000 | $0 |
| Purchase Of Intangibles | $-1,000,000 | $-2,000,000 | $-45,000,000 | $0 |
| Net PPE Purchase And Sale | $-66,000,000 | $-29,000,000 | $-8,000,000 | $-5,000,000 |
| Purchase Of PPE | $-66,000,000 | $-29,000,000 | $-8,000,000 | $-5,000,000 |
| Change In Working Capital | $-257,000,000 | $-46,000,000 | $-297,000,000 | $118,000,000 |
| Change In Other Current Liabilities | $41,000,000 | $8,000,000 | $110,000,000 | $-97,000,000 |
| Change In Other Current Assets | $49,000,000 | $377,000,000 | $-418,000,000 | $69,000,000 |
| Change In Payables And Accrued Expense | $-368,000,000 | - | $50,000,000 | $197,000,000 |
| Change In Accrued Expense | $-368,000,000 | $-387,000,000 | $50,000,000 | $197,000,000 |
| Change In Inventory | $18,000,000 | $-43,000,000 | $-6,000,000 | $-30,000,000 |
| Change In Receivables | $3,000,000 | $-1,000,000 | $-33,000,000 | $-21,000,000 |
| Changes In Account Receivables | $3,000,000 | - | - | - |
| Stock Based Compensation | $26,000,000 | $24,000,000 | $21,000,000 | $16,000,000 |
| Unrealized Gain Loss On Investment Securities | $0 | - | - | - |
| Asset Impairment Charge | $19,000,000 | - | - | - |
| Deferred Tax | $-46,000,000 | $7,000,000 | $-64,000,000 | $-105,000,000 |
| Deferred Income Tax | $-46,000,000 | $7,000,000 | $-64,000,000 | - |
| Depreciation Amortization Depletion | $20,000,000 | $28,000,000 | $15,000,000 | $16,000,000 |
| Depreciation And Amortization | $20,000,000 | $28,000,000 | $15,000,000 | $16,000,000 |
| Depreciation | $20,000,000 | $28,000,000 | $15,000,000 | $14,000,000 |
| Net Foreign Currency Exchange Gain Loss | $1,000,000 | $-2,000,000 | $-10,000,000 | $-4,000,000 |
| Net Income From Continuing Operations | $210,000,000 | $7,000,000 | $-126,000,000 | $-44,000,000 |
| Sale Of PPE | - | $1,000,000 | $162,000,000 | $0 |
| Other Non Cash Items | - | $1,000,000 | $161,000,000 | - |
| Gain Loss On Investment Securities | - | $9,000,000 | - | - |
| Sale Of Intangibles | - | - | $0 | $1,000,000 |
| Taxes Refund Paid | - | - | $-55,000,000 | $-67,000,000 |
| Interest Received Cfo | - | - | $42,000,000 | $15,000,000 |
| Interest Paid Cfo | - | - | $-32,000,000 | $-24,000,000 |
| Change In Other Working Capital | - | - | $49,000,000 | - |
| Change In Payable | - | - | $115,000,000 | $-98,000,000 |
| Amortization Cash Flow | - | - | $12,000,000 | $7,000,000 |
| Amortization Of Intangibles | - | - | $12,000,000 | - |
| Gain Loss On Sale Of PPE | - | - | $0 | $-1,000,000 |
Fetched: 2026-06-20